These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 37713703)

  • 1. Efficacy and Safety of Insulin Icodec Versus Glargine U100: A Meta-Analysis of Randomized Controlled Trials.
    Zerihun K; Mhanna M; Ayesh H; Ghazaleh S; Khader Y; Beran A; Aldhafeeri A; Sharma S; Iqbal A; Legesse H; Jaume J
    Am J Ther; 2023 Sep-Oct 01; 30(5):e480-e483. PubMed ID: 37713703
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and Safety of Insulin Icodec Versus Glargine U100: A Meta-Analysis of Randomized Controlled Trials: Erratum.
    Am J Ther; 2024 Mar-Apr 01; 31(2):e207. PubMed ID: 38518276
    [No Abstract]   [Full Text] [Related]  

  • 3. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    Rosenstock J; Bain SC; Gowda A; Jódar E; Liang B; Lingvay I; Nishida T; Trevisan R; Mosenzon O;
    N Engl J Med; 2023 Jul; 389(4):297-308. PubMed ID: 37356066
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Once-Weekly Insulin Icodec
    Ribeiro E Silva R; de Miranda Gauza M; Guisso MES; da Silva JON; Kohara SK
    Arch Endocrinol Metab; 2023 May; 67(5):e000614. PubMed ID: 37249450
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-Weekly Insulin for Type 2 Diabetes without Previous Insulin Treatment.
    Rosenstock J; Bajaj HS; Janež A; Silver R; Begtrup K; Hansen MV; Jia T; Goldenberg R;
    N Engl J Med; 2020 Nov; 383(22):2107-2116. PubMed ID: 32960514
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Once-Weekly Insulin Icodec Versus Once-Daily Insulin Glargine U100 in Type 2 Diabetes Inadequately Controlled on Daily Basal Insulin: A Phase 2 Randomized Controlled Trial.
    Bajaj HS; Bergenstal RM; Christoffersen A; Davies MJ; Gowda A; Isendahl J; Lingvay I; Senior PA; Silver RJ; Trevisan R; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1586-1594. PubMed ID: 33875485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (Ultra-)long-acting insulin analogues versus NPH insulin (human isophane insulin) for adults with type 2 diabetes mellitus.
    Semlitsch T; Engler J; Siebenhofer A; Jeitler K; Berghold A; Horvath K
    Cochrane Database Syst Rev; 2020 Nov; 11(11):CD005613. PubMed ID: 33166419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Randomized, Open-Label Comparison of Once-Weekly Insulin Icodec Titration Strategies Versus Once-Daily Insulin Glargine U100.
    Lingvay I; Buse JB; Franek E; Hansen MV; Koefoed MM; Mathieu C; Pettus J; Stachlewska K; Rosenstock J
    Diabetes Care; 2021 Jul; 44(7):1595-1603. PubMed ID: 33875484
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cardiovascular safety of long-acting insulin analogs in type 2 diabetes patients: Is there a better basal insulin?
    Chang CH; Chuang LM
    J Diabetes Investig; 2018 Jul; 9(4):728-730. PubMed ID: 29140602
    [No Abstract]   [Full Text] [Related]  

  • 10. Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Reply.
    Rosenstock J; Gowda A; Liang B
    N Engl J Med; 2023 Oct; 389(16):1533. PubMed ID: 37851884
    [No Abstract]   [Full Text] [Related]  

  • 11. Rationale and design of the phase 3a development programme (ONWARDS 1-6 trials) investigating once-weekly insulin icodec in diabetes.
    Philis-Tsimikas A; Bajaj HS; Begtrup K; Cailleteau R; Gowda A; Lingvay I; Mathieu C; Russell-Jones D; Rosenstock J
    Diabetes Obes Metab; 2023 Feb; 25(2):331-341. PubMed ID: 36106652
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoglycaemia frequency and physiological response after double or triple doses of once-weekly insulin icodec vs once-daily insulin glargine U100 in type 2 diabetes: a randomised crossover trial.
    Pieber TR; Arfelt KN; Cailleteau R; Hart M; Kar S; Mursic I; Svehlikova E; Urschitz M; Haahr H
    Diabetologia; 2023 Aug; 66(8):1413-1430. PubMed ID: 37308751
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical perspectives from the BEGIN and EDITION programmes: Trial-level meta-analyses outcomes with either degludec or glargine 300U/mL vs glargine 100U/mL in T2DM.
    Roussel R; Ritzel R; Boëlle-Le Corfec E; Balkau B; Rosenstock J
    Diabetes Metab; 2018 Nov; 44(5):402-409. PubMed ID: 29548798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A meta-analysis of rate ratios for nocturnal confirmed hypoglycaemia with insulin degludec vs. insulin glargine using different definitions for hypoglycaemia.
    Heller S; Mathieu C; Kapur R; Wolden ML; Zinman B
    Diabet Med; 2016 Apr; 33(4):478-87. PubMed ID: 26484727
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of insulin degludec versus insulin glargine U100 on time in range: SWITCH PRO, a crossover study of basal insulin-treated adults with type 2 diabetes and risk factors for hypoglycaemia.
    Goldenberg RM; Aroda VR; Billings LK; Christiansen ASL; Meller Donatsky A; Parvaresh Rizi E; Podgorski G; Raslova K; Klonoff DC; Bergenstal RM
    Diabetes Obes Metab; 2021 Nov; 23(11):2572-2581. PubMed ID: 34322967
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.
    Marso SP; McGuire DK; Zinman B; Poulter NR; Emerson SS; Pieber TR; Pratley RE; Haahr PM; Lange M; Brown-Frandsen K; Moses A; Skibsted S; Kvist K; Buse JB;
    N Engl J Med; 2017 Aug; 377(8):723-732. PubMed ID: 28605603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of IDegLira Versus Basal-Bolus Insulin Therapy in Patients With Type 2 Diabetes Uncontrolled on Metformin and Basal Insulin: The DUAL VII Randomized Clinical Trial.
    Billings LK; Doshi A; Gouet D; Oviedo A; Rodbard HW; Tentolouris N; Grøn R; Halladin N; Jodar E
    Diabetes Care; 2018 May; 41(5):1009-1016. PubMed ID: 29483185
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative safety and efficacy of insulin degludec with insulin glargine in type 2 and type 1 diabetes: a meta-analysis of randomized controlled trials.
    Zhang XW; Zhang XL; Xu B; Kang LN
    Acta Diabetol; 2018 May; 55(5):429-441. PubMed ID: 29423761
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of kidney function on the safety and efficacy of insulin degludec versus insulin glargine U300 in people with type 2 diabetes: A post hoc analysis of the CONCLUDE trial.
    Pieber TR; Bajaj HS; Heller SR; Jia T; Khunti K; Klonoff DC; Ladelund S; Leiter LA; Wagner L; Philis-Tsimikas A
    Diabetes Obes Metab; 2022 Feb; 24(2):332-336. PubMed ID: 34605127
    [No Abstract]   [Full Text] [Related]  

  • 20. Lower rates of hypoglycaemia in older individuals with type 2 diabetes using insulin degludec versus insulin glargine U100: Results from SWITCH 2.
    Heller SR; DeVries JH; Wysham C; Hansen CT; Hansen MV; Frier BM
    Diabetes Obes Metab; 2019 Jul; 21(7):1634-1641. PubMed ID: 30891886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.